Skip to main
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is well-positioned in the growing urology market, with its proprietary genomic tests improving prostate cancer diagnosis and providing actionable information. The company has a strong track record of making bolt-on acquisitions, including the recently acquired ExoDx test, and has indicated that it is evaluating further growth opportunities. Despite recent challenges with the Resolve UTI test, MDxHealth remains focused on its core cancer business and is expected to rebound and deliver strong growth in the coming years.

Bears say

MDxHealth is facing several headwinds in the near term, including a recent Q1 miss and a surprise material guidedown for 2026 due to a notice from Medicare contractor Novitas seeking a recoupment payment of ~$10M. Additionally, the company's decision to discontinue sales of its UTI test may impact its financial performance in the near future. The company also faces risks related to slower volume growth, reimbursement issues, and potential equity dilution.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.